Observations placeholder

Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).

Side effects

Common side effects

• Rash occurs in the majority of patients. This resembles acne and primarily involves the face and neck. It is self-limited and resolves in the majority of cases, even with continued use. Interestingly, some clinical studies have indicated a correlation between the severity of the skin reactions and increased survival though this has not been quantitatively assessed. The Journal of Clinical Oncology reported in 2004 that "cutaneous [skin] rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies." The newsletter Lung Cancer Frontiers reported in its October 2003 issue, "Patients with moderate to severe cutaneous reactions [rashes] have a far better survival, than those with only mild reactions and much better than those with no cutaneous manifestations of drug effects."
• Diarrhea
• Loss of appetite
• Fatigue
• Rarely, interstitial pneumonitis, which is characterized by cough and increased dyspnea. This may be severe and must be considered among those patients whose breathing acutely worsens.
• Rarely, ingrown hairs, such as eyelashes
• It has also been suggested that erlotinib can cause hearing loss.
• Partial hair loss (by strands, not typically in clumps)

Rare side effects

• gastrointestinal tract toxicity
  • serious or fatal gastrointestinal tract perforations
• skin toxicity
  • bullous, blistering, and exfoliative skin conditions (some fatal)
  • Stevens–Johnson syndrome/toxic epidermal necrolysis
• ocular disorders
  • corneal lesions
• Pulmonary toxicity
  • interstitial pneumonitis
  • bronchiolitis obliterans with organizing pneumonia (BOOP)
  • pulmonary fibrosis
  • fatal asymmetric interstitial lung disease

Time on Tarceva when people have Hallucination  :

Gender of people who have Hallucination when taking Tarceva  :

Age of people who have Hallucination when taking Tarceva  :

Severity of Hallucination when taking Tarceva  :

On Feb, 11, 2016: 6,685 people reported to have side effects when taking Tarceva. Among them, 1,504 people (22.50%) have Death.

Time on Tarceva when people have Death :

Gender of people who have Death when taking Tarceva  :

Age of people who have Death when taking Tarceva  :

Top conditions involved for these people :

1. Lung neoplasm malignant (75 people, 4.99%)
2. Non-small cell lung cancer (73 people, 4.85%)
3. Pancreatic carcinoma (25 people, 1.66%)
4. Bronchial carcinoma (11 people, 0.73%)
5. Lung carcinoma cell type unspecified stage 0 (11 people, 0.73%)